The cancer challenge is a global challenge, with 8 million deaths and over USD 1 trillion spent per year. The World Health Organisation estimates a 70% increase in cases over the next two decades.
Cancer is a disease that progresses in stages; it is typically diagnosed around Stage 2, by which time symptoms are often present and there is a higher risk the disease is so advanced that the chance of survival is relatively low; the earlier the cancer can be detected, the better for the patient and the lower the cost of treating that patient. Detecting cancer before symptoms become evident is the role of screening.
Several factors are considered when designing screening programmes, among them are the cost of each test to the tax payer, the prevalence of that cancer in the community and the accuracy of those tests. Tumour Trace’s technology aims to significantly reduce the cost of such tests whilst still providing diagnostic grade accuracy, allowing for screening programmes to be more extensive and available for all.
Opto-magnetic Imaging Spectroscopy (OMIS) is a patented technology for detecting cancerous tissue. It analyses light reflected from tissue under examination under different lighting conditions, and compares that light with known values for various stages of cancer. It uses machine learning to develop and improve its ability to detect cancerous tissue, and therefore must be trained.
Our objectives are to:
1. Further improve the accuracy of the OMIS technology;
2. Start multi-site head-to-head clinical trials throughout Europe on Cervical Cancer diagnosis, both fresh tissue and tissue from biobanks;
3. Sell our CE-marked products and services into Europe.
